IP Library Granted Patent US 7,700,328
Granted Patent B2
US 7,700,328 · App. 11/448,331 · Granted Apr 20, 2010

Method for producing an L-tyrosine over-producing bacterial strain

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,700,328
App. No.
11/448,331
Granted
Apr 20, 2010
Kind
B2
Abstract

An enteric bacterial strain was engineered to over-produce L-tyrosine using a one-step method. The pheA-tyrA chromosomal region of the bacterial genome was replaced with an engineered chromosomal segment, resulting in inactivation of the pheA coding region and strong expression of the tyrA coding region, resulting in high levels of L-tyrosine production.

Claims (17)

1. A method for making an L-tyrosine over-producing E. coli strain comprising:

a) providing a strain of E. coli ; and

b) replacing the endogenous pheA-tyrA chromosomal region of the E. coli strain with an engineered chromosomal segment comprising a nucleic acid fragment comprising:

1) a non-functional pheA coding region; and

2) a wild type tyrA coding region operably linked to a promoter;

wherein insertion of the engineered chromosomal segment generates the L-tyrosine over-producing E. coli strain.

2. The method according to claim 1 , wherein the E. coli strain is selected from the group consisting of K12, O157: H7, and CFT073.

3. The method according to claim 2 , wherein the E. coli strain is selected from the group consisting of ATCC #700926, ATCC #27325, ATCC #31882, ATCC #31884, and ATCC #13281.

4. The method according to claim 1 , wherein the engineered chromosomal segment optionally comprises a selection marker.

5. The method according to claim 1 , wherein the non-functional pheA nucleic acid sequence is a nucleic acid fragment comprising a deletion of at least a portion the pheA coding region.

6. The method according to claim 1 , wherein the E. coli strain further comprises a mutation selected from the group consisting aroG397 and tyrR366.

7. The method according to claim 1 , wherein the E. coli strain further comprises all of the following phenotypic traits:

a) resistance to 3-fluorotyrosine;

b) resistance to para-fluorophenylalanine; and

c) resistance to beta-2-thienylalanine.

8. The method according to claim 1 , wherein said promoter is selected from the group consisting of lac, ara, tet, trp, lambda P L, lambda P R , T7, tac, trc, malE, T3, T4, T5, rrnB, lpp, phoA, proU, cst-1, cadA, nar, cspA, gyrA, Bacillus spp nprM, and Streptomyces spp glucose isomerase.

9. The method according to claim 1 , wherein the L-tyrosine over-producing E. coli strain produces L-tyrosine at a concentration of at least 26 g/L.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE DESIGNATION OF ASSIGNEE AS A DELAWARE CORPORATION TO A DELAWARE LIMITED LIABILITY COMPANY PREVIOUSLY RECORDED ON REEL 049880 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 28, 2019
From: E. I. DU PONT DE NEMOURS AND COMPANY
To: DUPONT US HOLDING, LLC
Reel/Frame 051502/0610 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2019
From: E. I. DU PONT DE NEMOURS AND COMPANY
To: DUPONT US HOLDING, LLC
Reel/Frame 049880/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2006
From: GATENBY, ANTHONY A.; SUH, WONCHUL; PATNAIK, RANJAN; VAN DYK, TINA K.; SARIASLANI, FATEME SIMA
To: E. I. DU PONT DE NEMOURS AND COMPANY
Reel/Frame 017968/0738 →